Modern pharmacological treatments for anxiety disorders are safer and more tolerable than
they were 30 years ago. Unfortunately, treatment efficacy and duration have not improved in …

Anxiety disorders are the most prevalent psychiatric disorders and a leading cause of
disability. While there continues to be expansive research in posttraumatic stress disorder …

Given the enormous contribution of anxiety disorders to the burden of disease, it is key to
optimize their prevention and treatment. In this critical review we assess advances in the …

Abstract The Anxiety Disorders Association of America convened a conference of experts to
address treatment‐resistant anxiety disorders and review promising novel approaches to the …

Anxiety disorders, including panic disorder/agoraphobia (PDA), generalized anxiety
disorder (GAD), social anxiety disorder (SAD), and others, are the most prevalent mental …

This article reviews the evidence from randomized, placebo‐controlled trials and meta‐
analyses of pharmacological treatments of the following anxiety disorders: generalized …

Anxiety disorders affect one-eighth of the total population worldwide, and have become a
very important area of research interest in psychopharmacology. People with anxiety …

In this review, the author examines the evidence for psychopharmacologic treatments
among adults for generalized anxiety disorder, panic disorder, and social anxiety disorder …

The development of ethologically based behavioural animal models has clarified the
anxiolytic properties of a range of neurotransmitter and neuropeptide receptor agonists and …

Anxiety disorders, as a group, are among the most common mental health conditions and
frequently cause significant functional impairment. Both psychotherapeutic and …